Cyclopentolate is a muscarinic antagonist. It is commonly used as an eye drop during pediatric eye examinations to dilate the eye (mydriatic) and prevent the eye from focusing or accommodating (cycloplegic). Cyclopentolate or atropine can also be administered to reverse muscarinic and central nervous system effects of indirect cholinomimetic (anti-AChase) administration.
Market Analysis and Insights: Global Cyclopentolate Market
Due to the COVID-19 pandemic, the global Cyclopentolate market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Patent accounting for % of the Cyclopentolate global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Mydriatic Agent segment is altered to an % CAGR throughout this forecast period.
China Cyclopentolate market size is valued at US$ million in 2021, while the US and Europe Cyclopentolate are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Cyclopentolate landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Cyclopentolate include Alcon, Novartis, Laboratório Edol, Cadila Healthcare, FDC, Dr. Gerhard Mann, Abdi Ibrahim, Laboratorios Sophia and Bausch and Lomb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Cyclopentolate Scope and Segment
Cyclopentolate market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Cyclopentolate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Patent
Generic
Segment by Application
Mydriatic Agent
Muscarinic Receptor Antagonist
By Company
Alcon
Novartis
Laboratório Edol
Cadila Healthcare
FDC
Dr. Gerhard Mann
Abdi Ibrahim
Laboratorios Sophia
Bausch and Lomb
Santen
Riemser Arzneimittel
Teva
Akorn
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE